DX-8951f and Breast Cancer Resistance Protein in Ovarian Cancer
Author Information
Author(s): van Hattum A H, Hoogsteen I J, Schlüper H M M, Maliepaard M, Scheffer G L, Scheper R J, Kohlhagen G, Pommier Y, Pinedo H M, Boven E
Primary Institution: Vrije Universiteit Medical Center
Hypothesis
DX-8951f induces breast cancer resistance protein (BCRP) as a mechanism of resistance in ovarian cancer cells.
Conclusion
DX-8951f induces BCRP, but this results in only a minor reduction of its antitumor activity compared to other drugs.
Supporting Evidence
- DX-8951f-resistant cells showed a 9.3-fold resistance to DX-8951f compared to parental cells.
- BCRP expression was confirmed at both mRNA and protein levels in resistant cells.
- GF120918, a BCRP inhibitor, reversed resistance to DX-8951f in the resistant cell line.
Takeaway
Researchers found that a new cancer drug, DX-8951f, can make cancer cells resistant, but it still works better than some older drugs.
Methodology
The study involved creating a DX-8951f-resistant ovarian cancer cell line and testing drug resistance and expression of BCRP.
Limitations
The study primarily focused on a single cell line and may not represent all ovarian cancer types.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website